Physical activity · patients with promoting physical activity
Face‐to‐face interventions showed no clear difference in dichotomous outcomes: 12 months Self‐reported PA questionnaire compared with control (high certainty).
4 findings from 1 review
OR 1.58 [0.91, 2.75]
3 studies · 3261 participants
High
OR 1.19 [1.02, 1.39]
1 study · 2701 participants
High
no estimate extracted
3 studies · 4235 participants
High
Show 1 more finding
Cardio‐respiratory fitness: 12 months · patients with promoting physical activity
1 finding from 1 review
Physical activity · patients with promoting physical activity
Remote and web 2.0 probably leads to higher dichotomous outcomes: 12 months Self‐reported physical activity… compared with control (moderate certainty).
3 findings from 1 review
OR 1.42 [1.21, 1.66]
1 study · 1089 participants
Moderate
no estimate extracted
1 study · 1049 participants
Moderate
no estimate extracted
9 studies · 4547 participants
Moderate
Physical‐activity related outcomes · patients with promoting physical activity
Remote and web 2.0 showed no clear difference in dichotomous outcomes: 24 months Self‐reported physical activity… compared with control (moderate certainty).
1 finding from 1 review
All studies · patients with the initiation of oral anticoagulation
It is very uncertain whether 5 mg changes all studies compared with 10 mg (very low certainty).
1 finding from 1 review
Single INR measure · patients with the initiation of oral anticoagulation
It is very uncertain whether 5 mg changes single INR measure compared with 10 mg (very low certainty).
1 finding from 1 review
Consecutive INR measures · patients with the initiation of oral anticoagulation
It is very uncertain whether 5 mg changes consecutive INR measures compared with 10 mg (very low certainty).
1 finding from 1 review
All causes of mortality at 30 days · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days compared with anticoagulants (high certainty).
1 finding from 1 review
All causes of mortality at 30 days ‐ UFH · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days ‐ UFH compared with anticoagulants (high certainty).
1 finding from 1 review
All causes of mortality at 30 days ‐ Enoxaparin · Anticoagulants in ACS
Factor Xa inhibitors leads to lower all causes of mortality at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).
1 finding from 1 review
Major bleeding · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in major bleeding at 30 days compared with anticoagulants (high certainty).
2 findings from 1 review
Major bleeding at 30 days ‐ Enoxaparin · Anticoagulants in ACS
Factor Xa inhibitors leads to higher major bleeding at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).
1 finding from 1 review
Minor bleeding · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in minor bleeding at 30 days compared with anticoagulants (high certainty).
3 findings from 1 review
RR 0.7 [0.14, 3.39]
2 studies · 20404 participants
High
RR 1.76 [0.52, 5.94]
1 study · 326 participants
Moderate
RR 0.34 [0.28, 0.43]
1 study · 20078 participants
High
Intervention not reported
Wang 2006
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Intervention not reported
Zhou 1999
1 finding from 1 review
no estimate extracted
2 participants
GRADE not reported